RELIEF THERAPEUTICS HOLDING SA AND NRX PHARMACEUTICALS, INC. ANNOUNCE TENTATIVE SETTLEMENT OF PENDING LITIGATION

Release of an ad hoc announcement pursuant to Art. 53 LR

GENEVA and RADNOR, Pa., Aug. 22, 2022 /PRNewswire/ -- RELIEF THERAPEUTICS Holding SA (SIX:RLF) (OTCQB:RLFTF) (OTCQB:RLFTY) ("Relief"), and NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) ("NRx"), today announced that they have agreed to a tentative settlement of their pending litigation. The parties have agreed to work collaboratively to finalize the settlement within the next 30 days. Further, the parties have agreed to stay the litigation for an additional 60 days to allow for the negotiation and execution of the definitive settlement agreement and related terms. Terms of the settlement will be reported following execution of the definitive settlement documents, but any settlement may result in a re-allocation of the development rights and licensing arrangements for aviptadil. There can be no assurance that the parties will successfully complete the proposed settlement.